期刊
FEBS LETTERS
卷 584, 期 17, 页码 3800-3811出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.febslet.2010.06.009
关键词
Alternative Lengthening of Telomeres; ALT activity assay; ALT-associated PML body; Telomeric circle; ALT-positive cancer
资金
- Cancer Council New South Wales
- Cancer Institute New South Wales
- National Health and Medical Research Council of Australia
Alternative Lengthening of Telomeres (ALT) activity can be deduced from the presence of telomere length maintenance in the absence of telomerase activity. More convenient assays for ALT utilize phenotypic markers of ALT activity, but only a few of these assays are potentially definitive. Here we assess each of the current ALT assays and their implications for understanding the ALT mechanism. We also review the clinical situations where availability of an ALT activity assay would be advantageous. The prevalence of ALT ranges from 25% to 60% in sarcomas and 5% to 15% in carcinomas. Patients with many of these types of ALT[+] tumors have a poor prognosis. (C) 2010 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据